Company intelligence / Profile preview

Research Genetic Cancer Centre Group

Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

SOT therapy, based on siRNA-guided gene silencing and tailored to each patient's circulating tumor cell genomic profile, showed positive preliminary evaluations in roughly 78% of cancer patients, with KI (Karnofsky-Index) improvement in 72% of cases; aCGH platform exhibits high sensitivity/specificity for cancer of unknown primary

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotideSmall interfering RNALiquid biopsyGenomic profiling
Industry: Biotech

Drug pipeline

2 assets

Q-REstrain

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Research Genetic Cancer Centre Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Research Genetic Cancer Centre Group.

Explore the full profile